JPH05508860A - 細胞接着制御環状化合物 - Google Patents

細胞接着制御環状化合物

Info

Publication number
JPH05508860A
JPH05508860A JP91513631A JP51363191A JPH05508860A JP H05508860 A JPH05508860 A JP H05508860A JP 91513631 A JP91513631 A JP 91513631A JP 51363191 A JP51363191 A JP 51363191A JP H05508860 A JPH05508860 A JP H05508860A
Authority
JP
Japan
Prior art keywords
compound
phe
residue
diseases
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP91513631A
Other languages
English (en)
Japanese (ja)
Inventor
ロブル，トーマス・ジェイ
チャン，シュウーラン
カーダレリ，ピナ・エム
Original Assignee
田辺製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 田辺製薬株式会社 filed Critical 田辺製薬株式会社
Publication of JPH05508860A publication Critical patent/JPH05508860A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP91513631A 1990-07-09 1991-07-09 細胞接着制御環状化合物 Pending JPH05508860A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US550,330 1983-11-10
US07/550,330 US5192746A (en) 1990-07-09 1990-07-09 Cyclic cell adhesion modulation compounds
PCT/US1991/004862 WO1992000995A1 (en) 1990-07-09 1991-07-09 Cyclic cell adhesion modulation compounds

Publications (1)

Publication Number Publication Date
JPH05508860A true JPH05508860A (ja) 1993-12-09

Family

ID=24196720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP91513631A Pending JPH05508860A (ja) 1990-07-09 1991-07-09 細胞接着制御環状化合物

Country Status (6)

Country Link
US (1) US5192746A (enExample)
EP (1) EP0538399A1 (enExample)
JP (1) JPH05508860A (enExample)
CA (1) CA2087021A1 (enExample)
SG (1) SG72615A1 (enExample)
WO (1) WO1992000995A1 (enExample)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002914A1 (en) * 1987-09-28 1989-04-06 La Jolla Cancer Research Foundation Selection for cells having increased cell adhesion properties
US5643872A (en) * 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
CA2027936C (en) * 1989-10-23 2001-07-24 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5672585A (en) * 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5721210A (en) * 1990-07-09 1998-02-24 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
WO1992013958A1 (en) * 1991-02-06 1992-08-20 Georgetown University Receptor blocking peptides of fibroblast growth factor receptor
US5635477A (en) * 1991-09-30 1997-06-03 The Dupont Merck Pharmaceutical Company Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA
US5747447A (en) * 1992-04-30 1998-05-05 Cor Therapeutics Stable polypeptide composition
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
AU672010B2 (en) * 1992-06-04 1996-09-19 Aventis Inc. Conformationally restrained peptide analogs as antiplatelet agents
UA43823C2 (uk) * 1992-07-06 2002-01-15 Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН
WO1994005314A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
WO1994011398A1 (en) * 1992-11-18 1994-05-26 The Du Pont Merck Pharmaceutical Company CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa
US5591719A (en) * 1992-12-10 1997-01-07 Regents Of The University Of Minnesota Method for treating acute and chronic inflammatory disorders using polypeptides with fibronectin activity
US5710123A (en) * 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
US6380163B1 (en) 1992-12-22 2002-04-30 Baxter International Inc. Peritoneal dialysis solutions with polypeptides
WO1994022909A1 (en) * 1993-03-29 1994-10-13 The Du Pont Merck Pharmaceutical Company NOVEL PROCESSES AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF PLATELET CLYCOPROTEIN IIb/IIIa INHIBITORS
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
DE4310643A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
ATE195949T1 (de) * 1993-06-18 2000-09-15 Jolla Cancer Res Found Verfahren und zusammensetzungen zur behandlung der thrombose
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
DE4415310A1 (de) * 1994-04-30 1995-11-02 Merck Patent Gmbh Cyclopeptide
AU2958195A (en) * 1994-06-29 1996-01-25 Texas Biotechnology Corporation Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
AU682036B2 (en) * 1994-07-07 1997-09-18 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
US5811391A (en) * 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
US6056958A (en) * 1994-12-09 2000-05-02 Dupont Pharmaceuticals Method of treatment of arterial and venous thromboembolic disorders
GB9524630D0 (en) * 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US7001921B1 (en) 1995-01-23 2006-02-21 Biogen Idec Ma Inc. Cell adhesion inhibitors
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US5821329A (en) * 1996-06-06 1998-10-13 Tanabe Seiyaku Co., Ltd. Cyclic peptide inhibitors of β1 and β2 integrin-mediated adhesion
US5780426A (en) * 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
WO1996040781A1 (en) * 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
US6034057A (en) * 1995-07-06 2000-03-07 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
US5817750A (en) * 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
MX9704546A (es) * 1995-10-18 1997-10-31 Cor Therapeutics Inc MODULACION DE LA TRANSDUCCION DE SEñALES MEDIADA POR INTEGRINAS.
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
US6239108B1 (en) 1996-07-11 2001-05-29 Biogen, Inc. Cell adhesion inhibitors
US6686350B1 (en) 1996-07-25 2004-02-03 Biogen, Inc. Cell adhesion inhibitors
ES2285735T3 (es) 1996-07-25 2007-11-16 Biogen Idec Inc Modelo molecular para inhibidores de vla-4.
US6060588A (en) * 1996-11-18 2000-05-09 Cor Therapeutics, Inc. Bap-1 proteins
US6194557B1 (en) 1996-11-18 2001-02-27 Cor Therapeutics, Inc. Nucleic acid molecules encoding Bap-1 proteins
US6025150A (en) * 1996-11-21 2000-02-15 The Regents Of The University Of Michigan Methods and compositions for wound healing
US5840514A (en) * 1996-11-21 1998-11-24 The Regents Of The University Of Michigan Methods of testing cancer and anticancer drugs
US6331409B1 (en) 1996-11-21 2001-12-18 The Regents Of The University Of Michigan Methods and compositions for wound healing
US6001965A (en) * 1996-11-21 1999-12-14 The Regents Of The University Of Michigan Anticancer compounds and methods
US6274305B1 (en) 1996-12-19 2001-08-14 Tufts University Inhibiting proliferation of cancer cells
US6127520A (en) * 1997-04-15 2000-10-03 Regents Of The University Of Michigan Compositions and methods for the inhibition of neurotransmitter uptake of synaptic vesicles
AU743939B2 (en) * 1997-06-12 2002-02-07 Laboratoires Serono Sa CD28/CTLA-4 inhibiting peptidomimetics, pharmaceutical compositions thereof, and method of using same
GB9714276D0 (en) 1997-07-08 1997-09-10 Univ Dundee Peptides and related compounds
EP0970965A4 (en) 1997-11-13 2002-07-17 Toray Industries CYCLIC PEPTIDES AND MEDICAL USE THEREOF
ID28658A (id) * 1998-04-16 2001-06-21 Texas Biotechnology Corp Senyawa yang menghambat pengikatan integrin pada reseptornya
CN1148350C (zh) 1998-05-28 2004-05-05 拜奥根有限公司 新型VLA-4抑制剂:oMePUPA-V
BR9913705A (pt) 1998-09-14 2001-06-05 Univ Texas Métodos de tratamento de mieloma múltiplo e reabsorção de tecido ósseo induzido por mieloma utilizando antagonistas de integrin
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
US6329344B1 (en) 1998-10-22 2001-12-11 Ranbaxy Laboratories Limited Derivatives of monosaccharides as cell adhesion inhibitors
IN190975B (enExample) 1999-01-15 2003-09-06 Ranbaxy Lab Ltd
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6265572B1 (en) 1999-04-20 2001-07-24 Hoffmann-La Roche Inc. Pyrrolidincarbonylamino cyclic disulfide anti-inflammatory agents
EP1194157A4 (en) * 1999-04-21 2002-08-14 Hisamitsu Pharmaceutical Co D-FORM POLYPEPTIDES THAT GENERATE IMMUNOL TOLERANCE AND METHOD FOR THEIR USE
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6972296B2 (en) * 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
MXPA02001449A (es) 1999-08-13 2002-07-02 Biogen Inc Inhibidores de adhesion de celdas.
US6673346B1 (en) 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
ES2335643T3 (es) 1999-12-16 2010-03-31 Biogen Idec Ma Inc. Metodos de tratamiento de lesion isquemica o hemorragica del sistema nervioso central usando antagonistas anti-integrinas alfa 4.
EP1244656A1 (en) 1999-12-28 2002-10-02 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
US6875743B1 (en) 2000-11-28 2005-04-05 Biogen, Inc. Cell adhesion inhibitors
US20020146684A1 (en) * 2001-04-09 2002-10-10 Meldal Morten Peter One dimensional unichemo protection (UCP) in organic synthesis
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
WO2003019136A2 (en) * 2001-08-06 2003-03-06 The Regents Of The University Of California Methods for inhibiting angiogenesis
WO2003070892A2 (en) * 2002-02-15 2003-08-28 The Regents Of The University Of Michigan Inhibitors of rgs proteins
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US8557957B2 (en) 2003-01-03 2013-10-15 Elizabeth Kornecki Methods of treating disorders by administration of F11 receptor antagonists
US20050265992A1 (en) * 2003-01-03 2005-12-01 The Research Foundation Of State University Of New York F11 receptor (F11R) antagonists as therapeutic agents
TW200505945A (en) * 2003-05-16 2005-02-16 Sumitomo Electric Industries Oligopeptides
AU2004274051A1 (en) * 2003-09-22 2005-03-31 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US9403908B2 (en) 2003-09-29 2016-08-02 The Regents Of The University Of California Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration
WO2005070955A1 (en) * 2004-01-21 2005-08-04 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
US20050277575A1 (en) * 2004-03-24 2005-12-15 Alexandre Semov Therapeutic compositions and methods for treating diseases that involve angiogenesis
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
US20060078535A1 (en) * 2004-10-13 2006-04-13 The Regents Of The University Of Michigan Anticancer compounds and methods
EP1924276A4 (en) 2005-08-05 2009-07-22 Araim Pharmaceuticals Inc Antiperspirant peptides and their uses
CA2620934C (en) 2005-08-22 2014-07-22 Cornell Research Foundation, Inc. Compositions and methods for determining protein interactions using tat signal sequence and marker protein
EP1942947A4 (en) * 2005-10-04 2010-09-01 Res Foundation Of The State Un FIBRONECTIN POLYPEPTIDES AND METHOD OF USE
US8187883B2 (en) * 2005-10-21 2012-05-29 Wisconsin Alumni Research Foundation Method and system for delivering nucleic acid into a target cell
US8808698B2 (en) 2006-02-03 2014-08-19 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
WO2008045952A2 (en) * 2006-10-10 2008-04-17 The Regents Of The University Of Michigan Photoreceptor precursor cells
CA2690734A1 (en) * 2007-06-14 2008-12-24 Richard A. Clark Polypeptides and methods of use
US8466140B2 (en) * 2007-09-10 2013-06-18 University Of Massachusetts Mitochondria-targeted anti-tumor agents
US9096689B2 (en) 2007-11-07 2015-08-04 Northwestern University Methods and compositions for inhibiting angiogenesis
US8198406B2 (en) * 2007-11-07 2012-06-12 Northwestern University Methods and compositions for inhibiting angiogenesis
MX2010008050A (es) 2008-01-22 2011-02-23 Araim Pharmaceuticals Inc Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos.
JP5497006B2 (ja) 2008-04-14 2014-05-21 ザ ジェネラル ホスピタル コーポレイション 膵管腺癌の検出および治療のためのプレクチン−１標的化剤
KR101687037B1 (ko) 2008-06-09 2016-12-15 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
KR20110140128A (ko) 2009-03-27 2011-12-30 고조 인더스트리즈, 인크 포자-표면 상호작용을 길항하는 화합물을 스크리닝 및 사용하기 위한 조성물 및 방법
WO2010132537A1 (en) 2009-05-13 2010-11-18 The Regents Of The University Of Michigan Compounds for, and methods of, treating cancer and inhibiting invasion and metastases
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
CA2781402C (en) 2009-11-23 2017-03-21 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
WO2011063367A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
US9073974B2 (en) * 2009-12-21 2015-07-07 The Regents Of The University Of California RGD-containing cyclic peptides
WO2011123652A1 (en) 2010-04-02 2011-10-06 The Regents Of The University Of Michigan Rfamide-related peptides and methods thereof
DK3202789T3 (da) 2010-04-16 2020-05-18 Biogen Ma Inc Anti-vla-4-antistoffer
WO2013119923A1 (en) 2012-02-09 2013-08-15 The Regents Of The University Of Michigan Different states of cancer stem cells
HRP20211911T1 (hr) 2013-03-15 2022-03-18 Protagonist Therapeutics, Inc. Analozi hepcidina i njihova uporaba
EP3960754A3 (en) * 2014-05-16 2022-07-06 Protagonist Therapeutics, Inc. Alpha4beta7 integrin thioether peptide antagonists
AU2015289642B2 (en) 2014-07-17 2021-02-25 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
MX391184B (es) 2014-10-01 2025-03-19 Protagonist Therapeutics Inc ANTAGONISTAS DE MONOMÉRICOS Y DIMÉRICOS PEPTÍDICOS DE a4ß7 NOVEDOSOS.
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CN109310741A (zh) 2016-04-29 2019-02-05 阿拉伊姆药品公司 用于预防和治疗与组织损伤相关的疾病和障碍的组织保护肽
CA3040467C (en) 2016-10-14 2023-10-31 Neomatrix Therapeutics, Inc Peptides derived from fibronectin with improved bioactivity and reduced susceptibility to neutrophil elastase degradation
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
US10729741B2 (en) 2017-03-27 2020-08-04 Neomatrix Therapeutics Inc. Methods of treating burns with i.v. cP12 in a window from 2 to 6 hours after injury
US10875875B2 (en) 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
EP4501952A3 (en) 2018-02-08 2025-04-16 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
KR102848349B1 (ko) 2018-06-04 2025-08-21 바이오젠 엠에이 인코포레이티드 감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체
JP7560445B2 (ja) 2018-09-10 2024-10-02 コールド スプリング ハーバー ラボラトリー 膵炎を処置するための方法
US20220339248A1 (en) 2019-06-19 2022-10-27 The Research Foundation For The State University Of New York Methods for treating neointimal hyperlasia using f11r/jam-a inhibitors
CA3146390A1 (en) 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
TWI882061B (zh) 2020-01-15 2025-05-01 美商健生生物科技公司 介白素-23受體之肽抑制劑及其治療發炎性疾病之用途
US12018057B2 (en) 2020-01-15 2024-06-25 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
PE20240631A1 (es) 2020-11-20 2024-03-26 Janssen Pharmaceutica Nv Composiciones de inhibidores peptidicos del receptor de interleucina-23
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
EP0394326B1 (en) * 1987-12-10 1996-07-31 La Jolla Cancer Research Foundation Methods for the production of conformationally stabilized cell adhesion peptides
ZW6189A1 (en) * 1988-05-09 1990-05-09 Smithkline Beckman Corp Anti-aggregatory peptides
JP2945680B2 (ja) * 1988-09-09 1999-09-06 旭硝子株式会社 ペプチド誘導体およびその用途
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5384309A (en) * 1989-07-17 1995-01-24 Genentech, Inc. Cyclized peptides and their use as platelet aggregation inhibitors
EP0410539A1 (en) * 1989-07-28 1991-01-30 Merck & Co. Inc. Fibrinogen receptor antagonists
EP0410537A1 (en) * 1989-07-28 1991-01-30 Merck & Co. Inc. Fibrinogen receptor antagonists
EP0410541A1 (en) * 1989-07-28 1991-01-30 Merck & Co. Inc. Fibrinogen receptor antagonists
EP0410540A1 (en) * 1989-07-28 1991-01-30 Merck & Co. Inc. Fibrinogen receptor antagonists
CA2027936C (en) * 1989-10-23 2001-07-24 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
WO1991011458A1 (en) * 1990-02-02 1991-08-08 Genentech, Inc. CYCLIC PEPTIDES CONTAINING Arg-Gly-Asp FLANKED BY PROLINE
AU660926B2 (en) * 1990-04-06 1995-07-13 La Jolla Cancer Research Foundation Method and composition for treating thrombosis

Also Published As

Publication number Publication date
CA2087021A1 (en) 1992-01-10
SG72615A1 (en) 2000-05-23
US5192746A (en) 1993-03-09
WO1992000995A1 (en) 1992-01-23
EP0538399A4 (enExample) 1994-05-04
EP0538399A1 (en) 1993-04-28

Similar Documents

Publication Publication Date Title
JPH05508860A (ja) 細胞接着制御環状化合物
AU705717B2 (en) Fibronectin adhesion inhibitors
CA2140543C (en) Thrombin receptor antagonists
EP0677060A1 (en) Peptide inhibitors of cell adhesion
EP0422937B1 (en) Fibrinogen receptor antagonists
EP0478101B1 (en) Therapeutic use of peptides having thrombospondin-like activity
JPH03118330A (ja) フイブリノーゲンレセプター拮抗剤
JPH10506608A (ja) 白血球接着のインヒビター
WO1996040781A1 (en) CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
EP0570507A1 (en) Anti-aggregatory peptides containing an aromatic ester or amide
AU604279B2 (en) Peptide dimer which stimulates haemopoiesis
EP0514721B1 (en) Peptides having thrombospondin-like activity and their therapeutic use
US5721210A (en) Cyclic cell adhesion modulation compounds
US6207639B1 (en) Compounds and methods for modulating neurite outgrowth
US5719128A (en) Factor IIa inhibitors
WO1993000108A1 (en) Novel inhibitors of platelet aggregation
AU690923B2 (en) Linear adhesion inhibitors
US5648461A (en) Synthetic analogs of thrombospondin and therapeutic use thereof
CA2610496A1 (en) Synthetic peptide inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4
JP2000503649A (ja) 抗血栓剤および使用法
NZ260946A (en) Peptide cell adhesion inhibitors, pharmaceutical compositions, and diagnosis of disease
JPH0717999A (ja) ペプチド誘導体及びその用途